Summary
patients treated
Has anyone ever benefited from stem cell?
For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples’ lives and health.
FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.
List of patients
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 2901 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 2902 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 67 |
| 2903 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 47 |
| 2904 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 56 |
| 2905 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 55 |
| 2906 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 2907 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 66 |
| 2908 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 65 |
| 2909 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2910 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 69 |
| 2911 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2912 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Germany | 73 |
| 2913 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2914 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2020 | Standard Therapy | Poland | 69 |
| 2915 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2020 | Standard Therapy | Poland | 70 |
| 2916 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2917 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2020 | Standard Therapy | Poland | 62 |
| 2918 | Apheresis | Allogeneic | Myelofibrosis With Myeloid Metaplasia | Hematology | 2020 | Standard Therapy | Poland | 43 |
| 2919 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2920 | Apheresis | Allogeneic | Myeloma Multiplex | Hematology | 2020 | Standard Therapy | Poland | 52 |
| 2921 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2020 | Standard Therapy | Poland | 68 |
| 2922 | Apheresis | Allogeneic | Myeloproliferative Neoplasms | Hematology | 2020 | Standard Therapy | Poland | 40 |
| 2923 | Apheresis | Allogeneic | No Data | Hematology | 2020 | Standard Therapy | Poland | 71 |
| 2924 | Apheresis | Allogeneic | No Data | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 2925 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 65 |
| 2926 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 2927 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2928 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 2929 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 62 |
| 2930 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 53 |
| 2931 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 57 |
| 2932 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 69 |
| 2933 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 62 |
| 2934 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 34 |
| 2935 | Apheresis | Autologous | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 42 |
| 2936 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 62 |
| 2937 | Apheresis | Autologous | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2020 | Standard Therapy | Germany | 56 |
| 2938 | Apheresis | Autologous | Non-Hodgkin-Lymphoma-Relapse | Hematology | 2020 | Standard Therapy | Germany | 67 |
| 2939 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 68 |
| 2940 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 52 |
| 2941 | Apheresis | Allogeneic | Osteomyelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 2942 | Apheresis | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Hematology | 2020 | Standard Therapy | Poland | 57 |
| 2943 | Apheresis | Allogeneic | Perforin Deficiency | Hematology | 2020 | Standard Therapy | Poland | 2 |
| 2944 | Apheresis | Autologous | Primary Central Nervous System Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 59 |
| 2945 | Apheresis | Autologous | Primary Cerebral Diffuse Large B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 66 |
| 2946 | Apheresis | Autologous | Primary Cerebral Diffuse Large B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 59 |
| 2947 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 2948 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 2949 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 51 |
| 2950 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 66 |
| 2951 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 2952 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Germany | 54 |
| 2953 | Apheresis | Allogeneic | Primary Myelofibrosis | Hematology | 2020 | Standard Therapy | Germany | 58 |
| 2954 | Apheresis | Allogeneic | Purine Nucleoside Phosphorylase Deficiency | Hematology | 2020 | Standard Therapy | Poland | 1 |
| 2955 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 43 |
| 2956 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 76 |
| 2957 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 57 |
| 2958 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 66 |
| 2959 | Apheresis | Allogeneic | Secondary Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 56 |
| 2960 | Apheresis | Autologous | Secondary B-Cell Non-Hodgkin-Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 73 |
| 2961 | Apheresis | Autologous | Secondary Diffuse Large B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 54 |
| 2962 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2020 | Standard Therapy | Poland | 9 |
| 2963 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2020 | Standard Therapy | Poland | 53 |
| 2964 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2020 | Standard Therapy | Poland | 52 |
| 2965 | Apheresis | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2020 | Standard Therapy | Poland | 2 |
| 2966 | Apheresis | Allogeneic | Sezary Syndrome | Hematology | 2020 | Standard Therapy | Poland | 44 |
| 2967 | Apheresis | Allogeneic | T-Cell Acute Lymphoblastic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 14 |
| 2968 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 57 |
| 2969 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 29 |
| 2970 | Apheresis | Autologous | T-Cell Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 64 |
| 2971 | Apheresis | Allogeneic | T-Cell Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 63 |
| 2972 | Apheresis | Allogeneic | T-Cell-Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 29 |
| 2973 | Apheresis | Autologous | T-Cell-Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 51 |
| 2974 | Apheresis | Autologous | T-Cell-Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 60 |
| 2975 | Apheresis | Allogeneic | T-Cell-Prolymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 55 |
| 2976 | Apheresis | Allogeneic | T-Cell-Prolymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 74 |
| 2977 | Apheresis | Allogeneic | Β – Thalassemia | Hematology | 2020 | Standard Therapy | Poland | 6 |
| 2978 | Apheresis | Allogeneic | Β – Thalassemia Major | Hematology | 2020 | Standard Therapy | Poland | 17 |
| 2979 | Adipose Tissue | Autologous | Alopecia | Dermatology | 2020 | Experimental Therapy | Poland | 68,5 |
| 2980 | Adipose Tissue | Autologous | Chondromalacia | Orthopedy | 2020 | Experimental Therapy | Poland | 45,9 |
| 2981 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 52,8 |
| 2982 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 63,4 |
| 2983 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 41,1 |
| 2984 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 34,8 |
| 2985 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 48,1 |
| 2986 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 57,11 |
| 2987 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 59,8 |
| 2988 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 35,1 |
| 2989 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 61,8 |
| 2990 | Adipose Tissue | Autologous | Gonarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 56,5 |
| 2991 | Adipose Tissue | Autologous | Gonarthrosis; Shoulder Osteoarthritis | Orthopedy | 2020 | Experimental Therapy | Poland | 42,5 |
| 2992 | Adipose Tissue | Autologous | Internal Damage To The Knee Joint | Orthopedy | 2020 | Experimental Therapy | Poland | 53,6 |
| 2993 | Adipose Tissue | Autologous | Internal Damage To The Knee Joint | Orthopedy | 2020 | Experimental Therapy | Poland | 49,2 |
| 2994 | Adipose Tissue | Autologous | Omarthrosis | Orthopedy | 2020 | Experimental Therapy | Poland | 70,1 |
| 2995 | Adipose Tissue | Autologous | Other Acquired Deformities Of The Ankle And Foot | Orthopedy | 2020 | Experimental Therapy | Poland | 41,6 |
| 2996 | Adipose Tissue | Autologous | Scar | Dermatology | 2020 | Clinical Trial | Poland | no data |
| 2997 | Adipose Tissue | Autologous | Soft Tissue Diseases Related To Use, Overload And Pressure | Orthopedy | 2020 | Experimental Therapy | Poland | 61,1 |
| 2998 | Cord Tissue | Allogeneic – Unrelated | Limb-Girdle Muscular Dystrophy | Neurology | 2019 | Experimental Therapy | Poland | 5,3 |
| 2999 | Cord Tissue | Allogeneic – Unrelated | Acute Graft Versus Host Disease | Hematology | 2019 | Experimental Therapy | Poland | 1,9 |
| 3000 | Cord Tissue | Allogeneic – Unrelated | Acute Graft Versus Host Disease | Hematology | 2019 | Experimental Therapy | Poland | 6,1 |